Profile and Outcome of Children Treated for Multi-drug Resistant Gram-negative Bacterial Infection with Colistin or Polymyxin B in a Tertiary Hospital in the Philippines

Clicks: 12
ID: 327291
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #122 of 147 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 147 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background The rise of multidrug-resistant gram-negative bacteria (MDR-GNB) presents a critical challenge in pediatric care, necessitating the use of last-resort polymyxins. Data on the comparative safety and efficacy of Colistin versus Polymyxin B in children remain limited. This study describes the profile and outcomes of pediatric patients treated with these agents. Methods A retrospective cross-sectional study was conducted at a Philippine tertiary government hospital. Pediatric patients (0-18 years) with culture-proven MDR-GNB infections treated with Colistin or Polymyxin B from January 2019 to December 2023 were included. Data on demographic, clinical, microbiologic profiles, treatment outcomes, and adverse events were analyzed. Results Among 40 patients, 21 received Colistin and 19 received Polymyxin B. The median age was 1-5 years (37.5%), with a male predominance (77.5%). Most were underweight (77.5%) and admitted to the ICU (70%). Infections were predominantly hospital-acquired (90%). The most common isolates were Klebsiella pneumoniae (37.5%), Acinetobacter baumanii (25%), and E. coli (17.5%). Overall treatment success was high and comparable between Colistin (95.2%) and Polymyxin B (89.5%) groups (p=0.93). However, the mean duration of successful treatment was significantly longer in the Colistin group (49 days vs. 22.5 days, p<0.01). Clinical response time and rates of post-treatment infections were similar. Nephrotoxicity occurred in 7.5% of all patients, with no significant difference between groups (Colistin 4.76% vs. Polymyxin B 10.52%, p=0.65). No neurotoxicity was reported. Conclusion Both Colistin and Polymyxin B were effective and relatively safe for treating MDR-GNB infections in this pediatric cohort, demonstrating high treatment success and manageable toxicity profiles. The significantly longer treatment duration in the Colistin group warrants further investigation. These findings support the vigilant use of polymyxins in children while underscoring the need for continued monitoring and larger prospective studies to optimize therapy.
Reference Key
openalex_W7204634232 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kim Danielle S Fianza, Mary Crist D Jamora
Are you one of these authors? Claim your profile
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag070/piag070.050
URL
https://academic.oup.com/jpids/article-pdf/15/Supplement_2/S21/70833131/piag070.050.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.